Pharmaceutical Quality by Design
John Wiley & Sons Inc (Verlag)
978-1-118-89520-7 (ISBN)
Pharmaceutical Quality by Design: A Practical Approach outlines a new and proven approach to pharmaceutical product development which is now being rolled out across the pharmaceutical industry internationally. Written by experts in the field, the text explores the QbD approach to product development. This innovative approach is based on the application of product and process understanding underpinned by a systematic methodology which can enable pharmaceutical companies to ensure that quality is built into the product.
Familiarity with Quality by Design is essential for scientists working in the pharmaceutical industry. The authors take a practical approach and put the focus on the industrial aspects of the new QbD approach to pharmaceutical product development and manufacturing. The text covers quality risk management tools and analysis, applications of QbD to analytical methods, regulatory aspects, quality systems and knowledge management. In addition, the book explores the development and manufacture of drug substance and product, design of experiments, the role of excipients, multivariate analysis, and include several examples of applications of QbD in actual practice. This important resource:
Covers the essential information about Quality by Design (QbD) that is at the heart of modern pharmaceutical development
Puts the focus on the industrial aspects of the new QbD approach
Includes several illustrative examples of applications of QbD in practice
Offers advanced specialist topics that can be systematically applied to industry
Pharmaceutical Quality by Design offers a guide to the principles and application of Quality by Design (QbD), the holistic approach to manufacturing that offers a complete understanding of the manufacturing processes involved, in order to yield consistent and high quality products.
Editors Walkiria S. Schlindwein is Associate Professor of Pharmaceutics at the School of Pharmacy, De Montfort University. Walkiria is the programme leader of two Postgraduate courses in Pharmaceutical Quality by Design. Mark Gibson is Director of AM PharmaServices Ltd. He is a practicing Pharmaceutical Consultant and was formerly with AstraZeneca.
List of Figures xiii
List of Tables xix
List of Contributers xxi
Series Preface xxiii
Preface xxv
1 Introduction to Quality by Design (QbD) 1
Bruce Davis and Walkiria S. Schlindwein
1.1 Introduction 1
1.2 Background 2
1.3 Science] and Risk]Based Approaches 4
1.4 ICH Q8–Q12 5
1.5 QbD Terminology 6
1.6 QbD Framework 7
1.7 QbD Application and Benefits 7
1.8 Regulatory Aspects 8
1.9 Summary 9
1.10 References 9
2 Quality Risk Management (QRM) 11
Noel Baker
2.1 Introduction 11
2.2 Overview of ICH Q9 13
2.2.1 Start QRM Process 15
2.2.2 Risk Assessment 15
2.2.3 Risk Control 16
2.2.4 Risk Review 16
2.3 Risk Management Tools 17
2.4 Practical Examples of Use for QbD 22
2.4.1 Case Study 26
2.4.2 Pre]work 26
2.4.3 Scoring Meeting 32
2.4.4 FMECA Tool 32
2.4.5 Risk Score 32
2.4.6 Detectability Score 34
2.4.7 Communication 35
2.5 Concluding Remarks 36
2.6 References 44
3 Quality Systems and Knowledge Management 47
Siegfried Schmitt
3.1 Introduction to Pharmaceutical Quality System 47
3.1.1 Knowledge Management – What Is It and Why Do We Need It? 47
3.2 The Regulatory Framework 48
3.2.1 Knowledge Management in the Context of Quality by Design (QbD) 48
3.2.2 Roles and Responsibilities for Quality System 49
3.2.3 Roles and Responsibilities for Knowledge Management 50
3.2.4 Implicit and Explicit Knowledge 50
3.3 The Documentation Challenge 51
3.4 From Data to Knowledge: An Example 56
3.5 Data Integrity 58
3.6 Quality Systems and Knowledge Management: Common Factors for Success 58
3.7 Summary 59
3.8 References 60
4 Quality by Design (QbD) and the Development and Manufacture of Drug Substance 61
Gerry Steele
4.1 Introduction 61
4.2 ICH Q11 and Drug Substance Quality 62
4.2.1 Enhanced Approach 63
4.2.2 Impurities 63
4.2.3 Physical Properties of Drug Substance 64
4.3 Linear and Convergent Synthetic Chemistry Routes 65
4.4 Registered Starting Materials (RSMs) 67
4.5 Definition of an Appropriate Manufacturing Process 68
4.5.1 Crystallization, Isolation and Drying of APIs 68
4.5.2 Types of Crystallization 69
4.5.3 Design of Robust Cooling Crystallization 70
4.6 In]Line Process Analytical Technology and Crystallization Processes 78
4.6.1 Other Unit Operations 80
4.7 Applying the QbD Process 82
4.7.1 Quality Risk Assessment (QRA) 83
4.8 Design of Experiments (DoE) 87
4.9 Critical Process Parameters (CPPs) 88
4.10 Design Space 88
4.11 Control Strategy 89
4.12 References 91
5 The Role of Excipients in Quality by Design (QbD) 97
Brian Carlin
5.1 Introduction 97
5.2 Quality of Design (QbD) 98
5.3 Design of Experiments (DoE) 100
5.4 Excipient Complexity 102
5.5 Composition 105
5.6 Drivers of Functionality or Performance 105
5.7 Limited Utility of Pharmacopoeial Attributes 106
5.8 Other Unspecified Attributes 107
5.9 Variability 107
5.10 Criticalities or Latent Conditions in the Finished Product 108
5.11 Direct or Indirect Impact of Excipient Variability 110
5.12 Control Strategy 111
5.13 Communication with Suppliers 112
5.14 Build in Compensatory Flexibility 113
5.15 Risk Assessment 113
5.16 Contingencies 114
5.17 References 114
6 Development and Manufacture of Drug Product 117
Mark Gibson, Alan Carmody, and Roger Weaver
6.1 Introduction 117
6.2 Applying QbD to Pharmaceutical Drug Product Development 119
6.3 Product Design Intent and the Target Product Profile (TPP) 120
6.4 The Quality Target Product Profile (QTPP) 126
6.5 Identifying the Critical Quality Attributes (CQAs) 128
6.6 Product Design and Identifying the Critical Material Attributes (CMAs) 133
6.7 Process Design and Identifying the Critical Process Parameters (CPPs) 136
6.8 Product and Process Optimisation 139
6.9 Design Space 145
6.10 Control Strategy 150
6.11 Continuous Improvement 153
6.11 Acknowledgements 154
6.12 References 154
7 Design of Experiments 157
Martin Owen and Ian Cox
7.1 Introduction 157
7.2 Experimental Design in Action 158
7.3 The Curse of Variation 158
7.3.1 Signal]to]Noise Ratio 159
7.4 Fitting a Model 161
7.4.1 Summary of Fit 165
7.5 Parameter Estimates 165
7.6 Analysis of Variance 166
7.6.1 Reflection 168
7.7 ‘To Boldly Go’– An Introduction to Managing Resource Constraints using DoE 169
7.8 The Motivation for DoE 170
7.8.1 How Does the Workshop Exercise Work? 171
7.8.2 DoE Saves the Day! 172
7.9 Classical Designs 173
7.9.1 How Do Resource Constraints Impact the Design Choice? 173
7.9.2 Resource Implications in Practice 173
7.10 Practical Workshop Design 174
7.10.1 Choice of Factors and Measurements 175
7.10.2 Data Collection and Choice of Design 175
7.10.3 Some Simple Data Visualization 175
7.10.4 Analysis of the Half Fraction 177
7.10.5 How to Interpret Prediction Profiles 177
7.10.6 Half Fraction and Alternate Half Fraction 178
7.10.7 Interaction Effects 178
7.10.8 Full Factorial 181
7.10.9 Central Composite Design 181
7.10.10 How Robust Is This DoE to Unexplained Variation? 181
7.11 How Does This Work? The Underpinning of Statistical Models for Variation 184
7.12 DoE and Cycles of Learning 187
7.13 Sequential Classical Designs and Definitive Screening Designs 189
7.14 Building a Simulation 190
7.14.1 Sequential design, Part 1: Screening Design (10 Runs) 191
7.14.2 Sequential Design, Part II: Optimization Design (30 Runs) 191
7.14.3 Definitive Screening Design 194
7.14.4 Robustness Design 194
7.14.5 Additional Challenges 197
7.15 Conclusion 197
7.16 Acknowledgements 198
7.17 References 198
8 Multivariate Data Analysis (MVDA) 201
Claire Beckett, Lennart Eriksson, Erik Johansson, and Conny Wikstrom
8.1 Introduction 201
8.2 Principal Component Analysis (PCA) 202
8.3 PCA Case Study: Raw Material Characterization using Particle Size Distribution Curves 204
8.3.1 Dataset Description 204
8.3.2 Fitting a PCA Model to the 45 Training Set Batches 205
8.3.3 Classification of the 13 Test Set Batches 206
8.3.4 Added Value from DoE to Select Spanning Batches 208
8.4 Partial Least Squares Projections to Latent Structures (PLS) 208
8.5 PLS Case Study: A Process Optimization Model 210
8.5.1 Dataset Description 210
8.5.2 PLS Modeling of 85]Samples SOVRING Subset 211
8.5.3 Looking into Cause]and]Effect Relationships 212
8.5.4 Making a SweetSpot Plot to Summarize the PLS Results 213
8.5.5 Using the PLS]DoE Model as a Basis to Define a Design Space and PARs for the SOVRING Process 215
8.5.6 Summary of SOVRING Application 217
8.6 Orthogonal PLS (OPLS® Multivariate Software) 217
8.7 Orthogonal PLS (OPLS® Multivariate Software) Case Study – Batch Evolution Modeling of a Chemical Batch Reaction 218
8.7.1 Dataset Description 218
8.7.2 Batch Evolution Modeling 218
8.8 Discussion 220
8.8.1 The PAT Initiative 220
8.8.2 What Are the Benefits of Using DoE? 221
8.8.3 QbD and Design Space 222
8.8.4 MVDA/DoE Is Needed to Accomplish PAT/QbD in Pharma 223
8.8.5 MVDA: A Way to Power up the CPV Application 223
8.9 References 224
9 Process Analytical Technology (PAT) 227
Line Lundsberg]Nielsen,Walkiria S. Schlindwein, and Andreas Berghaus
9.1 Introduction 227
9.2 How PAT Enables Quality by Design (QbD) 229
9.3 The PAT Toolbox 229
9.4 Process Sensors and Process Analysers 229
9.4.1 Process Sensors – Univariate 233
9.4.2 Process Analysers – Multivariate 233
9.4.3 Infrared (IR) 233
9.4.4 Near Infrared (NIR) 238
9.4.5 Tunable Diode Laser Spectroscopy (TDLS) 239
9.4.6 Ultraviolet]Visible (UV]Vis) 239
9.4.7 Raman 239
9.4.8 Focused Beam Reflectance Measurements (FBRM) and Laser Diffraction 239
9.4.9 Particle Vision and Measurement (PVM) 239
9.4.10 X]Ray Fluorescence (XRF) 240
9.4.11 Imaging Technologies 240
9.5 Analyser Selection 240
9.6 Regulatory Requirements Related to PAT Applications 240
9.6.1 Europe 242
9.6.2 United States 242
9.7 PAT Used in Development 242
9.8 PAT Used in Manufacturing 243
9.9 PAT and Real Time Release Testing (RTRT) 245
9.10 PAT Implementation 245
9.11 Data Management 246
9.12 In]Line Process Monitoring with UV]Vis Spectroscopy: Case Study Example 247
9.13 References 253
10 Analytical Method Design, Development, and Lifecycle Management 257
Joe de Sousa, David Holt, and Paul A. Butterworth
10.1 Introduction 257
10.2 Comparison of the Traditional Approach and the Enhanced QbD Approach 258
10.3 Details of the Enhanced QbD Approach 260
10.4 Defining Method Requirements 262
10.5 Designing and Developing the Method 264
10.6 Understanding the Impact of Method Parameters on Performance 266
10.7 Defining the Method Control Strategy and Validating the Method 267
10.8 Monitoring Routine Method Performance for Continual Improvement 268
10.9 Summary 269
10.10 Example Case Studies 270
10.10.1 Case Study 1 – Establishment of Robust Operating Ranges during Routine Method Use and Justifying the Method Control Strategy (Including SST Criteria) 270
10.10.2 Risk Assessment and Definition of Ranges 270
10.10.3 Experimental Design 271
10.10.4 Evaluate the DoE 272
10.10.5 Documenting Method Performance 274
10.10.6 Case Study 2 – Evaluation of the Ruggedness of a Dissolution Method for a Commercial Immediate Release Tablet Product 274
10.10.7 Case Study Acknowledgements 278
11 Manufacturing and Process Controls 281
Mark Gibson
11.1 Introduction to Manufacturing and Facilities 281
11.2 Validation of Facilities and Equipment 282
11.2.1 The International Society for Pharmaceutical Engineering (ISPE) Baseline® Guide: Commissioning and Qualification 282
11.2.2 ASTM E2500]07: Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment 284
11.2.3 Science]Based Approach and Critical Aspects 285
11.2.4 Risk]Based Approach 286
11.2.5 System and Component Impact Assessments 288
11.2.6 URSs for Systems 290
11.2.7 Specification and Design 290
11.2.8 Verification 290
11.3 Drug Product Process Validation: A Lifecycle Approach 292
11.3.1 Stage 1: Process Design/Product Development 295
11.3.2 Stage 2: Process Qualification 298
11.3.3 Stage 3: Continued Process Verification 299
11.4 The Impact of QbD on Process Equipment Design and Pharmaceutical Manufacturing Processes 300
11.5 Introduction to Process Control in Pharmaceutical Manufacturing 302
11.6 Advanced Process Controls (APC) and Control Strategy 305
11.7 The Establishment of Continuous Manufacture 309
11.8 The Tablet Press as Part of a Continuous Tableting Line 312
11.9 Real]Time Release Testing and Continuous Quality Verification 316
11.10 Acknowledgments 317
11.11 References 317
12 Regulatory Guidance 321
Siegfried Schmitt and Mustafa A. Zaman
12.1 Introduction 321
12.2 The Common Technical Document (CTD) Format 322
12.2.1 Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs) 324
12.2.2 Quality Risk Management (ICH Q9) 324
12.2.3 Product and Process Development (S.2.6 and P.2) 325
12.2.4 Control Strategy 326
12.2.5 Design Space (Optional) 327
12.3 Essential Reading 328
12.4 What Is Not Written, or Hidden, in the Guidance Documents? 329
12.5 Post]Approval Change 330
12.6 Summary 331
12.7 References 332
Index
| Erscheinungsdatum | 13.06.2018 |
|---|---|
| Reihe/Serie | Advances in Pharmaceutical Technology |
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 175 x 246 mm |
| Gewicht | 885 g |
| Themenwelt | Naturwissenschaften ► Chemie ► Technische Chemie |
| Technik | |
| ISBN-10 | 1-118-89520-7 / 1118895207 |
| ISBN-13 | 978-1-118-89520-7 / 9781118895207 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
